Protalix BioTherapeutics Inc. | |
Stock Exchange | NYSE |
EPS |
$0.18 |
Market Cap |
$66.74 M |
Shares Outstanding |
148.3 M |
Public Float |
136.43 M |
Address |
2 Snunit Street Carmiel HZ 21614 Israel |
Employees | - |
Website | http://www.protalix.com |
Updated | 07/08/2019 |
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. |